NCT03065374View on ClinicalTrials.gov

Treatment for Clostridium-difficile Infection With IMM529

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

November 7, 2019

Study Completion Date

November 7, 2019

Conditions

Clostridium Difficile InfectionClostridium Difficile Infection Recurrence

Interventions

BIOLOGICAL

IMM-529

IMM-529

OTHER

Placebo

Matching placebo

Trial Locations (2)

Unknown

Hadassah Medical Center, Jerusalem

Sheba Hospital, Tel Litwinsky

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Immuron Ltd.

INDUSTRY

NCT03065374 - Treatment for Clostridium-difficile Infection With IMM529 | Biotech Hunter | Biotech Hunter